Cancer Therapy : Clinical Phase II Study of Everolimus ( RAD 001 ) in Previously Treated Small Cell Lung Cancer

Ahmad Tarhini,Athanasios Kotsakis,William Gooding,Yongli Shuai,Daniel Petro,David Friedland,Chandra P. Belani,Sanja Dacic,Athanassios Argiris

semanticscholar（2010）

引用 0|浏览0

暂无评分

摘要

Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in previously treated, relapsed

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要